Medical Society Issues Testosterone Therapy Guidelines Emphasizing Accurate Diagnosis

A major medical society has released new clinical guidance on testosterone replacement therapy, and the message is clear: getting the diagnosis right matters more than rushing to treatment. The guideline, focused on men with hypogonadism, emphasizes that symptoms alone—fatigue, low libido, mood changes—are not enough to justify starting therapy. These complaints are common in aging men and have many possible causes, from obesity to medications like corticosteroids or opioids. A clinician must first rule out these reversible contributors before considering testosterone as the answer.

The actual diagnosis of hypogonadism requires two things working together: a man must report symptoms of low testosterone, and blood tests must consistently show low levels of both total and free testosterone. This sounds straightforward, but there's a catch. Testing across different laboratories often produces wildly different results from the same blood sample. One lab's "low" is another lab's "normal." This diagnostic chaos means some men get treated who shouldn't be, while others who genuinely need therapy go without it. The guideline calls for standardized testosterone assays—tests that produce consistent, reliable results—and recommends that diagnosis be based on at least two early-morning, fasting testosterone measurements, with a common clinical threshold near 300 ng/dL.

The society also warns against vague diagnostic categories like "age-related hypogonadism" or "late-onset hypogonadism." These terms blur the line between actual disease and the normal changes that come with aging, making it harder to know who truly needs treatment. There is not enough evidence, the guideline states, to recommend screening asymptomatic men for low testosterone at the population level. The focus should be on men who have both symptoms and confirmed low hormone levels.

When testosterone replacement therapy is appropriate—particularly for men whose hypogonadism stems from a problem with the testes, pituitary, or hypothalamus—the benefits are clear. But for men who are overweight or obese with no other identified cause, weight loss should be tried first. And here's where the picture gets more complicated. Recent large trials involving more than 5,200 men found no meaningful increase in heart attacks or strokes over one to four years of treatment. That's reassuring. But the same trials showed roughly a 50 percent relative increase in pulmonary embolism—blood clots in the lungs—and an increased rate of bone fractures among men receiving testosterone. Long-term safety, particularly regarding prostate cancer risk, remains unclear. Prostate cancer develops slowly, and the trials may not have followed men long enough to catch delayed effects.

Because of these lingering questions, the society emphasizes that screening and careful monitoring must continue throughout treatment. Risk assessment before starting therapy and vigilant follow-up during treatment are essential. The guideline also calls for a long-term research initiative modeled on the Women's Health Initiative—a major government-funded study that tracked women's health outcomes over decades. A comparable Men's Health Initiative could help close the evidence gaps that currently exist around testosterone therapy's long-term effects. Until then, the message is measured: testosterone replacement has a place, but only for men with accurate diagnosis, careful consideration of risks, and close medical supervision.